ZoomInfo Does It Again: Earns Top Ratings in TrustRadius' Customer-Verified Awards
VANCOUVER, Wash.--(BUSINESS WIRE)-- ZoomInfo (NASDAQ: GTM), the Go-To-Market Intelligence Platform, was recognized with TrustRadius' Top Rated Awards for customer satisfaction in nine categories.
ZoomInfo's suite of AI-powered B2B solutions and data are helping organizations from the mid-market to Fortune 500 companies empower their sales, marketing and operations teams - all in one operating system.
Share
Established in 2016 to distinguish products with excellent customer satisfaction, the TrustRadius Top Rated Awards are based on verified customer reviews, recognizing excellent B2B technology products. ZoomInfo Marketing joins the company's other best-in-class offerings in 2025, sweeping three categories of its own.
Top Rated Honors in:
'We're building the GTM platform for the enterprise that unifies data, insights, and execution,' ZoomInfo Founder and CEO Henry Schuck said. 'It's incredibly validating to see that our solutions are solving real pain points for our customers across the entire revenue organization. We're committed to delighting our customers and helping them sell smarter and win faster.'
ZoomInfo's suite of AI-powered B2B solutions and data are helping organizations from the mid-market to Fortune 500 companies empower their sales, marketing and op erations teams - all in one operating system. With Go-To-Market Intelligence, revenue teams can precisely target customers and align their motions to the ways buyers actually make decisions through intelligent engagement. This allows teams to work smarter, move faster, and drive revenue growth.
About ZoomInfo
ZoomInfo (Nasdaq: GTM) is the Go-To-Market Intelligence Platform that empowers businesses to grow faster with AI-ready insights, trusted data, and advanced automation. Its solutions provide more than 35,000 companies worldwide with a complete view of their customers, making every seller their best seller. ZoomInfo is a recognized leader in data privacy, with industry-leading GDPR and CCPA compliance and numerous data security and privacy certifications. For more information about how ZoomInfo can help businesses with go-to-market intelligence that accelerates revenue growth, please visit www.zoominfo.co m.
About TrustRadius
TrustRadius delivers the most credible buyer intelligence platform, helping buyers confidently make decisions with comprehensive, vetted product information and customer-generated content. Technology providers are empowered to tell their unique stories, engage high-intent buyers, and gain customer insights. Founded by successful entrepreneurs and headquartered in the technology hub of Austin, Texas, TrustRadius is backed by Mayfield Fund, LiveOak Venture Partners, and Next Coast Ventures.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Anthony Pompliano eyes a $750M Bitcoin SPAC merger
Anthony Pompliano eyes a $750M Bitcoin SPAC merger originally appeared on TheStreet. Crypto entrepreneur and podcast host Anthony Pompliano is reportedly in talks to launch a new Bitcoin fund that, if launched, would provide indirect access to Bitcoin to more institutional investors. The vehicle, which will be called ProCapBTC, will be headed up by Pompliano himself in the role of CEO. However, his position at the leadership of the vehicle is currently under debate, according to the Financial Times. ProCapBTC, on the other hand, intends to complete a combination with Columbus Circle Capital 1, a blank-check company that went public with support from the investment bank Cohen & Company. The proposed raise would be $500 million in equity and $250 million in convertible debt, with an announcement potentially coming next week. Columbus Circle Capital 1 is a newly incorporated blank check company formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with a high-growth technology, industrial, or consumer company. It pulled in $250 million in its May 2025 IPO underwritten by Cohen & Company Capital Markets (CCM), a unit of JVB Financial Group. NYSE-listed Cohen & Company is increasingly involved in the cryptocurrency sector, providing tax, audit, and advisory services related to digital assets, DeFi, NFTs, and cryptocurrency exchanges. Pompliano is a vocal Bitcoin proponent who already leads a fintech-focused special purpose acquisition company (SPAC), ProCap Acquisition, which went public on the Nasdaq in April. That entity raised $250 million in its initial public offering (IPO) and trades under the ticker symbol PCAPU. Shares of PCAPU advanced in June, opening at $10.60 on June 1 and rising to $11.40 by the beginning of this week, but settled at $11.42 on June 13. Anthony Pompliano eyes a $750M Bitcoin SPAC merger first appeared on TheStreet on Jun 13, 2025 This story was originally reported by TheStreet on Jun 13, 2025, where it first appeared. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
4 minutes ago
- Yahoo
MicroStrategy director cashes out $10M
MicroStrategy director cashes out $10M originally appeared on TheStreet. Strategy (Nasdaq: MSTR), earlier known as MicroStrategy, director Carl Rickertsen has cashed out all his MSTR shares for more than $10 million this month. Helmed by co-founder and executive chairman Michael Saylor, Strategy is the world's largest public corporate holder of Bitcoin. As of now, the company holds 582,000 BTC worth a whopping $61.25 billion. As per Strategy, Rickertsen has been its board member since October 2002. Protos reported about the recent transactions made by Rickertsen in a news story on June 12. As per Protos, Rickertsen bought $700,000 in MSTR shares in 2022 and sold half of it in 2023. Now, he has let go of all of his MSTR holdings. On June 2, Rickertsen acquired 26,390 shares and then sold the same day for $9,827,636. On 3 June, he sold 980 shares for $371,488.60 that he had acquired on May 13. Notably, Strategy began acquiring Bitcoin in 2020 amidst the coronavirus pandemic, and the MSTR stock has since grown more than 3,100% in value since then. The recent Iran-Israel conflict led to the stock dipping as the market opened on June 13, but it managed to recover later. At press time, MSTR was trading at $379.82. Meanwhile, Bitcoin has grown more than 1,100% in value since 2020. As per Kraken, Bitcoin was trading at $105,245.08 at press time, down 2.81% a day. TheStreet Roundtable reached out to MicroStrategy for a comment on the matter and has not received a response so far. We will update the story if and when the company responds. MicroStrategy director cashes out $10M first appeared on TheStreet on Jun 13, 2025 This story was originally reported by TheStreet on Jun 13, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
Prime Success Responds to Sinovac Biotech's False and Misleading Claims
HONG KONG--(BUSINESS WIRE)--Prime Success L.P., (together with its affiliates, 'Prime Success' or 'we'), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) ('Sinovac' or the 'Company') with ownership of approximately 8% of the Company's outstanding shares, today issued the following letter in response to the Company's recent false and misleading claims relating to the upcoming Special Meeting of Shareholders (the 'Special Meeting') scheduled for July 8, 2025. The full text of the letter is below and available at Dear fellow Sinovac shareholders, Prime Success, L.P. (together with its affiliates, 'Prime Success' or 'we'), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) ('Sinovac' or the 'Company'), continues to be disappointed by the current Board's ('1Globe Activist Board') distortion of the facts about what is at stake at the upcoming Special Meeting of Shareholders (the 'Special Meeting') scheduled for July 8, 2025. In our June 10 letter we addressed several of the 1Globe Activist Board's misstatements and are taking the opportunity to remind all shareholders why the 1Globe Activist Board cannot be trusted: 1. Prime Success is insisting that a dividend be distributed – for all shareholders The 1Globe Activist Board's false comments are just not credible – why would any investor be against receiving a dividend? The 1Globe Activist Board wants you to believe that Prime Success is the reason that dividends have not been distributed, but we are not the Company and are not on the Board, and dividend distribution decisions are not ours to make. We can only continue to advocate on behalf of all shareholders that they should be made. Under the leadership of a SAIF Partners IV L.P. ('SAIF') nominated Board — composed of seasoned professionals with proven governance experience, deep operational insight, and a track record of building real, lasting value — we are confident that the pattern of internal conflict and ongoing litigation fueled by the 1Globe Activist Board can be broken, and shareholders can look forward to more future dividends. But that will not be possible with the 1Globe Activist Board in power as they have made clear they prioritize endless litigation over the Company's long-term success. 2. The 1Globe Activist Board is deliberately baiting shareholders by setting the dividend distribution date for one day after the Special Meeting. We call upon the Company to make dividend distribution before the Special Meeting The 1Globe Activist Board deliberately set the dividend date for one day after the Special Meeting which creates the false impression that shareholders must vote for the incumbents to receive the dividends. But the upcoming Special Meeting will determine the Company's future direction and the long-term interests of all shareholders. We call on the 1Globe Activist Board to allow for a fair, pro rata distribution of dividends and to move the date of the dividend distribution to before the Special Meeting so the meeting can refocus on its proper purpose: electing a competent Board. 3. The 1Globe Activist Board distorts historic facts to aggrandize 1Globe and smear legitimate investors Let's compare facts against rhetoric of the 1Globe Activist Board. Over the past seven years, what have we contributed to the Company? The critical lifeline investments from Prime Success and Vivo Capital, LLC, combined with management's determined efforts, enabled Sinovac to seize a pivotal opportunity: the development of CoronaVac. This initiative ultimately resulted in the delivery of billions of doses to over 60 countries, generating substantial revenues while saving countless lives. Without the success of CoronaVac, there would not be any sizable dividend to distribute now. In contrast, what has 1Globe done for the Company? It has initiated multi-jurisdictional litigation against Sinovac, leading to a waste of company resources. The 1Globe Activist Board's mischaracterization of 1Globe and Prime Success' relative contribution to Sinovac and its shareholders reveals its deeply partisan nature. 4. Shareholders: looking forward, it's time to focus on what truly matters – the future of your investment in Sinovac Sinovac needs a Board that will roll up its sleeves and run the business, guiding the Company forward on a stable, productive path. The slate put forward by SAIF, consisting of representatives from all shareholders owning more than 5% of the Company's equity stake, many of whom possess deep industry experience, achieves exactly that. We urge all shareholders to focus on the future and choose the leadership that will best secure our Company's success in the years to come. We look forward to continuing to make our case for change to our fellow shareholders and encourage them to wait for and read SAIF's proxy materials before voting for the Special Meeting on July 8, 2025. Sincerely, Prime Success, L.P. About Prime Success, L.P. Prime Success is an investment vehicle established by Advantech Capital specifically to invest in Sinovac and Sinovac Life Sciences; Advantech Capital is a private equity fund established in 2016 with a focus on innovation-driven growth opportunities in China.
